RLAY Stock Forecast & Price Target

Relay Therapeutics is viewed favorably because its zovegalisib program has already shown exceptionally strong data in vascular anomalies, with expansion cohorts now enrolling adolescents and adults aged 12 years and older and a regulatory/data update expected by end-2026. The company also has multiple shots on goal in breast cancer, including an ongoing Phase 3 ReDiscover-2 study and a planned front-line Phase 3 regimen, while a pooled dataset of 109 patients and a 44% ORR in later-line triplet therapy strengthen confidence in the broader franchise. Financially, 2Q26 net loss of $0.41 per share was manageable, cash of $910.9M supports an operational runway into 2029, and elevated short interest of 24.51% of the public float adds upside if upcoming catalysts confirm the pipeline’s promise.

Relay Therapeutics is viewed negatively because its valuation depends heavily on a speculative 75% probability of approval for zovegalisib in 1L and 2L PI3Kα+, HR+, HER2- mBC, while the business still faces substantial clinical, regulatory, and competitive risk. The company’s DCF-based projected market value only shifts from $6.3B to $6.2B despite those assumptions, underscoring how sensitive the thesis is to trial outcomes and approval timing rather than proven commercial execution. It is also likely to require additional equity financing to advance its pipeline, creating medium- to long-term dilution risk for shareholders, while a change in fair value of contingent consideration liability of (13,206) signals added financial complexity.